mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.039 |
0.2 |
mRNA |
PF-4708671 |
GDSC1000 |
pan-cancer |
AAC |
0.042 |
0.2 |
mRNA |
tanespimycin:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.039 |
0.2 |
mRNA |
PI-103 |
GDSC1000 |
pan-cancer |
AAC |
0.037 |
0.2 |
mRNA |
HG-5-88-01 |
GDSC1000 |
pan-cancer |
AAC |
0.056 |
0.2 |
mRNA |
Cetuximab |
GDSC1000 |
pan-cancer |
AAC |
0.039 |
0.2 |
mRNA |
Parthenolide |
GDSC1000 |
pan-cancer |
AAC |
0.064 |
0.2 |
mRNA |
Cyclopamine |
GDSC1000 |
pan-cancer |
AAC |
0.064 |
0.2 |
mRNA |
GSK1059615 |
CTRPv2 |
pan-cancer |
AAC |
0.054 |
0.2 |
mRNA |
Bosutinib |
CTRPv2 |
pan-cancer |
AAC |
-0.041 |
0.2 |